Evidence map›Paper›PMID 36988872›Full record

ArticleObesity (Silver Spring, Md.)2023

Metabolic dysfunction in obesity is related to impaired suppression of fatty acid release from adipose tissue by insulin.

Michael W Schleh, Benjamin J Ryan, Cheehoon Ahn, Alison C Ludzki, Pallavi Varshney, Jenna B Gillen, Douglas W Van Pelt, Lisa M Pitchford, Suzette M Howton, Thomas Rode and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Michael W SchlehSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-9969-6316
Benjamin J RyanSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-5848-6988
Cheehoon AhnSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-4140-125X
Alison C LudzkiSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-6967-034X
Pallavi VarshneySubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
Jenna B GillenSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
Douglas W Van PeltSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-9594-604X
Lisa M PitchfordSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-6402-0823
Suzette M HowtonSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
Thomas RodeSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
Thomas L ChenevertDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Scott L HummelDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-0924-3135
Charles F BurantDivision of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Jeffrey F HorowitzSubstrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-3851-777X
University of Michigan · USUniversity of Toronto · CA

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Scott Soleimanpour · 2013 to 2026
$24.3M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joyce Lee · 2010 to 2026
$20.3M
Statistics and Bioinformatics Core - WangU24DK097153 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BURANT, CHARLES F · 2012 to 2017
$10.1M
TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM.T32DK007245 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RICHARD J. AUCHUS · 1986 to 2026
$7.2M
Insulin sensitivity and fatty acid partitioning in skeletal muscle after exerciseR01DK077966 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOROWITZ, JEFFREY F · 2010 to 2020
$4.9M
The role of iron in adipose tissue lipolysis, systemic fatty acid mobilization, and insulin resistance in obese humansF32DK117522 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RYAN, BENJAMIN · 2018 to 2020
$87k
NIDDK NIH HHS F32 DK117522NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK077966NIDDK NIH HHS T32 DK007245NIDDK NIH HHS U24 DK097153
6 · The paper itself

Abstract

objectiveThe aims of this study were: 1) to assess relationships among insulin-mediated glucose uptake with standard clinical outcomes and deep-phenotyping measures (including fatty acid [FA] rate of appearance [FA Ra] into the systemic circulation); and 2) to examine the contribution of adipocyte size, fibrosis, and proteomic profile to FA Ra regulation.

methodsA total of 66 adults with obesity (BMI = 34 [SD 3] kg/m

resultsInsulin-mediated FA Ra suppression associated with insulin-mediated glucose uptake (r = 0.51; p < 0.01) and negatively correlated with liver (r = -0.36; p < 0.01) and visceral fat (r = -0.42; p < 0.01). aSAT proteomics from subcohorts of participants with low FA Ra suppression (n = 8) versus high FA Ra suppression (n = 8) demonstrated greater extracellular matrix collagen protein in low versus high FA Ra suppression. Skeletal muscle lipidomics (n = 18) revealed inverse correlations of FA Ra suppression with acyl-chain length of acylcarnitine (r = -0.42; p = 0.02) and triacylglycerol (r = -0.51; p < 0.01), in addition to insulin-mediated glucose uptake (acylcarnitine: r = -0.49; p < 0.01, triacylglycerol: r = -0.40; p < 0.01).

conclusionsInsulin's ability to suppress FA release from aSAT in obesity is related to enhanced insulin-mediated glucose uptake and metabolic health in peripheral tissues.

Indexed as

InsulinInsulin ResistanceAdipose TissueAdultCarnitineFatty AcidsGlucoseGlucose Clamp TechniqueHumansObesityProteomicsTriglyceridesacylcarnitineCarnitineFatty AcidsGlucoseInsulinTriglycerides

Identifiers

PMID36988872
PMCPMC10192005
OpenAlexW4361295108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.